Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.66 Insider Own0.60% Shs Outstand43.04M Perf Week7.82%
Market Cap468.71M Forward P/E- EPS next Y-0.51 Insider Trans-91.78% Shs Float42.39M Perf Month-10.30%
Income-23.40M PEG- EPS next Q-0.23 Inst Own87.00% Short Float11.72% Perf Quarter-3.80%
Sales29.50M P/S15.89 EPS this Y60.90% Inst Trans-2.34% Short Ratio7.99 Perf Half Y30.58%
Book/sh1.70 P/B6.41 EPS next Y51.00% ROA-32.90% Target Price16.72 Perf Year77.07%
Cash/sh2.41 P/C4.52 EPS next 5Y- ROE-60.70% 52W Range5.52 - 13.64 Perf YTD-3.71%
Dividend- P/FCF- EPS past 5Y11.10% ROI-7.60% 52W High-20.16% Beta-
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low97.28% ATR0.76
Employees27 Current Ratio15.20 Sales Q/Q1548.20% Oper. Margin-22.70% RSI (14)47.25 Volatility5.51% 7.65%
OptionableYes Debt/Eq0.20 EPS Q/Q200.00% Profit Margin-79.30% Rel Volume0.80 Prev Close10.89
ShortableYes LT Debt/Eq0.20 EarningsApr 28 Payout- Avg Volume622.46K Price10.89
Recom1.70 SMA20-1.09% SMA50-6.78% SMA2003.81% Volume0 Change0.00%
17-Apr-14Initiated Canaccord Genuity Buy $16
07-Jan-14Initiated RBC Capital Mkts Outperform $15
19-Dec-13Reiterated Mizuho Buy $18 → $20
17-Dec-13Reiterated MLV & Co Buy $15 → $16.50
17-Jul-13Reiterated Mizuho Neutral $13 → $18
04-Feb-13Initiated MLV & Co Buy $13
30-Jan-13Initiated Mizuho Buy $13
10-Oct-12Resumed Canaccord Genuity Buy $8
26-May-11Initiated Canaccord Genuity Buy $6
17-Apr-14 07:57AM  Coverage initiated on AcelRx by Canaccord Genuity Briefing.com
04-Apr-14 07:30AM  AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference PR Newswire
01-Apr-14 05:05PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
25-Mar-14 05:03PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
07:30AM  AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer PR Newswire
21-Mar-14 01:04PM  ACELRX PHARMACEUTICALS INC Financials EDGAR Online Financials
17-Mar-14 05:19PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
07-Mar-14 04:45PM  AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference PR Newswire -8.38%
05-Mar-14 05:01PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online +6.54%
04-Mar-14 01:43PM  Why AcelRx Pharmaceuticals, Inc. Shares Popped Today at Motley Fool +8.81%
03-Mar-14 11:29PM  AcelRx Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
11:29PM  AcelRx Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
04:05PM  AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results PR Newswire
07:07AM  Q4 2013 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN
24-Feb-14 07:30AM  AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014 PR Newswire
14-Feb-14 08:30AM  Significant Upcoming Catalysts For These Biotechs Should Provide Alpha Opportunity at Seeking Alpha
08:30AM  Significant Upcoming Catalysts For These Biotechs Should Provide Alpha Opportunity
10-Feb-14 05:16PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
09:35AM  Mallinckrodt Beats Q1 Earnings, Ups View Zacks
05-Feb-14 07:30AM  AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events PR Newswire
07-Jan-14 06:11AM  Coverage initiated on AcelRx by RBC Capital Mkts Briefing.com +5.39%
06:11AM  Coverage initiated on AcelRx by RBC Capital Mkts
23-Dec-13 08:59AM  These Small-Cap BioPharma Companies Have Catalysts Upcoming at Seeking Alpha
08:59AM  These Small-Cap BioPharma Companies Have Catalysts Upcoming
19-Dec-13 05:27PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online +10.30%
05:27PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
05:17PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online
07:30AM  AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital PR Newswire
07:30AM  AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
18-Dec-13 01:31PM  Nasdaq stocks posting largest percentage increases AP
17-Dec-13 06:02PM  Nasdaq stocks posting largest percentage increases AP
01:29PM  Nasdaq stocks posting largest percentage increases AP
06:22AM  AcelRx Pharmaceuticals (ACRX) Jumps: Stock Up 17.9% Zacks
06:22AM  AcelRx Pharmaceuticals (ACRX) Jumps: Stock Up 17.9%
16-Dec-13 06:07PM  Nasdaq stocks posting largest percentage increases AP +17.93%
05:18PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
05:18PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
03:36PM  Big Biotech ETF to Add Some New Holdings; Others Depart ETF Trends
03:36PM  Big Biotech ETF to Add Some New Holdings; Others Depart
08:05AM  Annual Changes to the NASDAQ Biotechnology Index GlobeNewswire
08:05AM  Annual Changes to the NASDAQ Biotechnology Index
07:30AM  AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO PR Newswire
07:30AM  AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO
13-Dec-13 07:30AM  AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference PR Newswire
07:30AM  AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
11-Dec-13 07:30AM  AcelRx Pharmaceuticals Adds New Board Member PR Newswire
05-Dec-13 06:05PM  NDA for AcelRx's Zalviso Accepted Zacks
04-Dec-13 06:02PM  Nasdaq stocks posting largest percentage increases AP
01:24PM  Nasdaq stocks posting largest percentage increases AP
03-Dec-13 06:11PM  Nasdaq stocks posting largest percentage increases AP -7.23%
02-Dec-13 06:03PM  Nasdaq stocks posting largest percentage increases AP
03:47PM  Nasdaq stocks posting largest percentage increases AP
07:36AM  InPlay: AcelRx announces that the Zalviso NDA was accepted for filing by the FDA on Nov 26, 2013 Briefing.com
07:33AM  AcelRx announces FDA acceptance of Zalviso NDA theflyonthewall.com
07:30AM  Zalviso New Drug Application Accepted for Filing by FDA PR Newswire
29-Nov-13 05:54PM  Nasdaq stocks posting largest percentage increases AP +11.39%
27-Nov-13 01:54PM  AcelRx: Huge Potential With Limited Risk at Seeking Alpha +5.78%
26-Nov-13 07:30AM  AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference PR Newswire
14-Nov-13 01:04PM  ACELRX PHARMACEUTICALS INC Financials EDGAR Online Financials
13-Nov-13 03:08PM  5 Stocks With Big Insider Buying at TheStreet +6.54%
05-Nov-13 11:34PM  AcelRx Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
06:11PM  U.S./Canada daily earnings hits & misses Nov 5 - 1800 ET Reuters
05:22PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:42PM  InPlay: AcelRx reports Q3 adjusted loss of $0.21 a share; revenue recognized during the qtr was $0.5 mln vs $0.2 mln in the yr-ago. No estimates available. Briefing.com
04:05PM  AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results PR Newswire
11:40AM  Insider Trading: Buys at Freeport-McMoRan, Horsehead Holding, AcelRx at Minyanville
09:01AM  Top Insider Trades: ACW ZINC ACRX FCX at TheStreet
07:07AM  Q3 2013 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN
22-Oct-13 07:30AM  AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013 PR Newswire -8.39%
15-Oct-13 06:05PM  Nasdaq stocks posting largest percentage decreases AP
01:22PM  Nasdaq stocks posting largest percentage decreases AP
08:00AM  Our Best Small-Cap Biotech Picks For The Rest Of This Year at Seeking Alpha
07:39AM  InPlay: AcelRx announces data presentations for Zalviso at US and international medical meetings; Results demonstrated that patients receiving Zalviso realized a significantly greater SPID-48 during the study period than placebo-treated pat Briefing.com
07:30AM  AcelRx Pharmaceuticals Announces Data Presentations for Zalviso at US and International Medical Meetings PR Newswire
14-Oct-13 06:05PM  Nasdaq stocks posting largest percentage decreases AP -7.27%
09-Oct-13 04:05PM  AcelRx Gives Patent Update Zacks -7.07%
08-Oct-13 07:32AM  InPlay: AcelRx provides update on its patent portfolio for Zalviso and its proprietary platform technologies; Patent estate includes nine issued U.S. patents, nineteen patents worldwide Briefing.com -9.41%
07:30AM  AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso and its Proprietary Platform Technologies PR Newswire
07-Oct-13 06:03PM  Nasdaq stocks posting largest percentage decreases AP -5.93%
02:15PM  Nasdaq stocks posting largest percentage decreases AP
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WAN MARK ADirectorMar 10Sale12.36835,32710,324,642126,153Mar 11 02:34 PM
WAN MARK ADirectorMar 07Sale12.30164,6732,025,400137,403Mar 11 02:34 PM